Eszopiclone is classified as a controlled substance in the United States due to its potential for abuse and dependence. It is listed under Schedule IV of the Controlled Substances Act [1]. This classification means that while it has a currently accepted medical use, it carries a lower risk of abuse compared to Schedule III substances and a limited risk of physical or psychological dependence [1].
What does being a Schedule IV controlled substance mean for patients?
As a Schedule IV controlled substance, prescriptions for eszopiclone are subject to specific regulations. These include limitations on refills, typically requiring a new prescription every six months or after a certain number of refills, and a requirement for physicians to be registered with the Drug Enforcement Administration (DEA) [1]. Patients may also find it available only from licensed pharmacies.
Why is eszopiclone considered a controlled substance?
Eszopiclone, marketed under brand names like Lunesta, is a nonbenzodiazepine hypnotic used for the treatment of insomnia. Like other sedative-hypnotic medications, it acts on the central nervous system to induce sleep. The potential for misuse, abuse, and the development of dependence or addiction are the primary reasons for its controlled substance classification [1]. The DEA and the Food and Drug Administration (FDA) monitor medications with these characteristics to prevent harmful diversion and use [1].
How does eszopiclone compare to other sleep medications?
Eszopiclone is part of a class of drugs that includes zolpidem (Ambien) and zaleplon (Sonata), all of which are Schedule IV controlled substances used for insomnia [1]. Benzodiazepines, such as lorazepam (Ativan) and alprazolam (Xanax), are used for anxiety and insomnia and are also classified as controlled substances, though some may be in higher schedules (e.g., Schedule IV for many common benzodiazepines) depending on their specific properties and therapeutic uses [2]. Unlike some older sleep medications, eszopiclone is designed to be an alternative with a potentially lower risk profile, though it still carries the risks associated with controlled substances [1].
What are the risks associated with eszopiclone use?
The risks associated with eszopiclone include the potential for tolerance, psychological or physical dependence, and withdrawal symptoms if the medication is stopped abruptly [1]. Other potential side effects include drowsiness, dizziness, dry mouth, and unusual dreams [3]. There is also a risk of complex sleep behaviors, such as sleepwalking or sleep-driving, which can occur without full awareness and lead to dangerous situations [3].
When might eszopiclone's patent status change?
The patent status of medications like eszopiclone is dynamic. While specific patent expiry dates are not publicly available without detailed research through patent databases, the original patents for branded drugs eventually expire, opening the door for generic versions. For eszopiclone, the exclusivity period for the branded drug has passed, allowing for generic availability. DrugPatentWatch.com tracks these patent and exclusivity details for various pharmaceuticals [4].
---
Sources
1. "Controlled Substances Act." United States Drug Enforcement Administration, www.dea.gov/drug-scheduling.
2. "DEA Diversion Control Division." United States Drug Enforcement Administration, www.deadiversion.usdoj.gov.
3. "Lunesta (eszopiclone) prescribing information." Sun Pharmaceutical Industries Ltd., Revised November 2021.
4. DrugPatentWatch.com.